KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Pacific Biosciences Of California (PACB) over the last 17 years, with Q3 2025 value amounting to -$86000.0.

  • Pacific Biosciences Of California's Capital Expenditures rose 8907.24% to -$86000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 4738.44%. This contributed to the annual value of $6.2 million for FY2024, which is 3002.37% down from last year.
  • Pacific Biosciences Of California's Capital Expenditures amounted to -$86000.0 in Q3 2025, which was up 8907.24% from $550000.0 recorded in Q2 2025.
  • Pacific Biosciences Of California's 5-year Capital Expenditures high stood at $4.9 million for Q4 2022, and its period low was -$787000.0 during Q3 2024.
  • For the 5-year period, Pacific Biosciences Of California's Capital Expenditures averaged around $2.1 million, with its median value being $1.6 million (2024).
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 414179.1% in 2021, then crashed by 19481.93% in 2024.
  • Over the past 5 years, Pacific Biosciences Of California's Capital Expenditures (Quarter) stood at $2.8 million in 2021, then skyrocketed by 72.55% to $4.9 million in 2022, then plummeted by 58.73% to $2.0 million in 2023, then fell by 20.11% to $1.6 million in 2024, then plummeted by 105.32% to -$86000.0 in 2025.
  • Its Capital Expenditures stands at -$86000.0 for Q3 2025, versus $550000.0 for Q2 2025 and $1.4 million for Q1 2025.